EMEA-001169-PIP01-11-M05
Key facts
Invented name |
Praluent
|
Active substance |
Alirocumab
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0550/2021
|
PIP number |
EMEA-001169-PIP01-11-M05
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of elevated cholesterol
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Sanofi-Aventis Recherche & Développement
Tel. +33 169745695 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|